Cochrane Database of Systematic Reviews 2009
DOI: 10.1002/14651858.cd007107.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy

Abstract: There is no evidence for or against antibiotics compared to G(M)-CSFs for the prevention of infections in cancer patients.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
34
0

Year Published

2009
2009
2016
2016

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 62 publications
(34 citation statements)
references
References 87 publications
0
34
0
Order By: Relevance
“…Many cancer patients receiving chemotherapy and/or radiotherapy develop hematopoietic and immune suppression that can lead to dose reductions and delays in therapy [14]. Dose reductions and treatment delays can compromise the outcomes of cancer therapy and decrease overall survival and disease-free survival [1, 47].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Many cancer patients receiving chemotherapy and/or radiotherapy develop hematopoietic and immune suppression that can lead to dose reductions and delays in therapy [14]. Dose reductions and treatment delays can compromise the outcomes of cancer therapy and decrease overall survival and disease-free survival [1, 47].…”
Section: Introductionmentioning
confidence: 99%
“…Dose reductions and treatment delays can compromise the outcomes of cancer therapy and decrease overall survival and disease-free survival [1, 47]. However, strategies to effectively reduce the undesirable collateral effects of these therapies, and accelerate the recovery of depressed hematopoietic and immune functions after chemotherapy and/or radiotherapy remains a major clinical problem.…”
Section: Introductionmentioning
confidence: 99%
“…In addition, an estimated 60,000 patients with cancer are hospitalized each year in the United States for chemotherapy-induced neutropenia and, among those hospitalized, about 4,100 will die from this complication (Caggiano, Weiss, Rickert, & Linde-Zwirble, 2005). Neutropenia and subsequent infectious complications are among the most serious treatment-related toxicities of cancer treatment and result in preventable morbidity and mortality (Herbst et al, 2009; Lyman et al, 2010). Infections among immunosuppressed patients with cancer are life-threatening, with a mortality rate associated with febrile neutropenia of 2%–21%, depending on the cancer type, type of chemotherapy, and other factors (Herbst et al, 2009; Lyman et al, 2010; Smith et al, 2006).…”
mentioning
confidence: 99%
“…Neutropenia and subsequent infectious complications are among the most serious treatment-related toxicities of cancer treatment and result in preventable morbidity and mortality (Herbst et al, 2009; Lyman et al, 2010). Infections among immunosuppressed patients with cancer are life-threatening, with a mortality rate associated with febrile neutropenia of 2%–21%, depending on the cancer type, type of chemotherapy, and other factors (Herbst et al, 2009; Lyman et al, 2010; Smith et al, 2006). Infections can be difficult to identify in this vulnerable population given a lack of clinical signs and symptoms from neutropenia and a decreased febrile response (Lyman et al, 2010).…”
mentioning
confidence: 99%
See 1 more Smart Citation